EP News Bureau

Partnership aims to expand access to treatment options for Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies

The single-dose vial is bioequivalent to Hospira’s reference product and will enter the US market later this year

Company to distribute and promote the once-weekly injectable therapy following Lilly’s DCGI approval

Approval enables access to targeted therapy for adults and adolescents aged 12 and above following surgery

Biocon Group Chairperson recognised in Mumbai ceremony for contributions to global healthcare and biotechnology

Formycon to develop and supply Pembrolizumab biosimilar FYB206, while Zydus Lifesciences will commercialise the product in the USA…

GlobalData data shows increases in mergers, acquisitions and venture funding activity year-on-year

Deal covers commercialisation and development rights outside key regulated markets

Company shares regulatory milestone and product details

Indian-origin pharma leader represented Russia in bilateral trade discussions